For diagnostic products and other products and services, supplement the income and proportion of the above-mentioned products and services from their own agent sales and self-produced and self-developed sales during the reporting period, the proportion in the total main business income, the contribution profit and the proportion in the net profit; (2) Supplement the cooperation background and development process between the issuer and the top five major authorized agent brands during the reporting period, the amount and proportion of products purchased by the issuer from the brand, the form of agency authorization, main rights and obligations of the contract, agency term, renewal mode, renewal of agency authorization about to expire, interest sharing, whether agency fee and minimum purchase amount are agreed, and whether rebate is agreed; Whether there are agreements on core technology and intangible assets between the issuer and each brand agent and authorizer; The business essence of the issuer’s agent sales, whether the issuer purchases and stores the goods and owns the ownership of the goods it sells, the way of interest sharing with the brand, whether it has agreed on downstream sales channels, specific customers, or whether there is an agreement on bundle sales; Specific differences between exclusive agent and primary agent, regional scope of agent, rights, obligations and interest agreements between the issuer and secondary agent; (3) In combination with the relevant provisions on the import, export, agency sales, R & D and production of medical reagents and equipment in China, whether the various products sold by the issuer and produced by itself meet the relevant legal requirements for prior approval, whether the issuer has the relevant assets for import agency sales and export sales, whether the self-developed and produced reagents and equipment products need prior approval, and whether the relevant R & D and production personnel have complete qualifications, Whether relevant laboratories meet the grade requirements; (4) Distinguish specific product categories and explain the proportion of direct sales, distribution and domestic and overseas sales revenue of each product; The basic information and cooperation background of the top five dealers and the top five overseas customers during the reporting period, including products, production and sales mode, sales amount and proportion in total revenue, and whether there is any relationship with the issuer, actual controller, directors, supervisors and senior executives; (5) In combination with the main regulatory laws of the issuer’s industry and the relevant management regulations on the types of downstream customers, explain whether the issuer’s sales of medical reagents and equipment for downstream scientific research institutions, colleges, subordinate troops and hospitals of the people’s Liberation Army should be approved and filed with the local competent administrative department and the army, and whether the relevant products should be approved by the competent administrative department and the army for inspection and acceptance, Whether it should be continuously used under supervision; During the reporting period, whether the issuer has been punished and held accountable by the relevant competent departments and troops for the unqualified acceptance of the delivered products, medical safety accidents in subsequent use; The legal liability of the issuer in case of the above circumstances; Quantity, amount and proportion of returned products of the issuer during the reporting period; (6) Supplement the proportion of the issuer winning customers by bidding during the reporting period; In combination with the types of downstream customers of the issuer, explain whether all sales to such types of customers should comply with the bidding procedures; Whether there is any situation that bidding should be conducted but not in the reporting period, and if so, explain the compliance and rationality. Ask the sponsor, the issuer’s lawyer and the reporting accountant to express their clear opinions. (audit inquiry question 1)
（1） Distinguish between life scientific research reagents, scientific research instruments, pathological diagnosis equipment, other pathological diagnosis products, and other products and services, and respectively supplement the income and proportion of the above products and services from their own agent sales and self-produced self-developed sales during the reporting period, the proportion in the total main business income, the contribution profit and the proportion in the net profit
1. Composition of income from various products and services of the company by agent brand and independent brand
During the reporting period, the composition of the company’s revenue from various products and services by agent brand and independent brand and the proportion in the main business revenue are as follows:
Unit: 10000 yuan,%
January September 20212020 20192018
Product category and brand
Proportion of income proportion of income proportion of income proportion of income proportion of income
Own brand 203382 3.47215552 3.57162602 3.75147309 4.50 scientific research reagent
Agent brand 4170424 71.234069241 67.403238977 74.712335786 71.29 life science research products
Research instrument agent brand 390658 6.67428041 7.09310432 7.16304228 9.29
Subtotal 4764463 81.384712834 78.063712012 85.622787323 85.07
Self owned brand 566387 9.67509840 8.44274243 6.33149507 4.56 pathological diagnosis equipment
Agent brand 10.98 0.03 18.81 0.06
Pathological diagnosis products independent brand 36.01 0.06 20.32 0.03 16.08 0.04 15.83 0.05 other pathological diagnosis products
Agent brand 33.81 0.06 134.34 0.22 65.62 0.15 57.45 0.18
Subtotal 573369 9.79525306 8.70283511 6.54158717 4.84
Independent brand 172.57 0.29 439.84 0.73 297.27 0.69 229.90 0.70 blood collection equipment
Agent brand 115336 1.97189938 3.15302651 6.98305048 9.31
Independent brand of immunodiagnostic reagent 187.17 0.32 76.19 0.13 21.34 0.05
Other products virus preservation reagent independent brand 346540 5.92526037 8.71
Independent brand of experimental service 118.97 0.20 140.63 0.23 43.63 0.10 18.07 0.06
Other agent brands 69.97 0.12 178.52 0.30 10.23 0.02 4.76 0.01
Subtotal 516743 8.83799495 13.24339898 7.84330320 10.08
Subtotal of agent brands 4686795 80.054718506 78.153860745 89.052953164 90.14
Subtotal of independent brands 1167780 19.951319128 21.85474676 10.95323196 9.86
Total main business income 5854576 100.006037634 100.004335421 100.003276360 100.00
As shown in the above table, during the reporting period, the company mainly sold agent brands, including scientific research reagents, scientific research instruments and blood collection equipment. The overall income of agent brand products was 295316400 yuan, 386074500 yuan, 471850600 yuan and 468679500 yuan respectively, accounting for 90.14%, 89.05%, 78.15% and 80.05% of the main business income respectively. With the continuous technology accumulation and R & D, The pathological diagnosis products, scientific research reagents, virus preservation reagents and other products of the company’s own brand have developed rapidly. The income of the products of the company’s own brand is 323196 million yuan, 474676 million yuan, 1319128 million yuan and 116778 million yuan respectively, accounting for 9.86%, 10.95%, 21.85% and 19.95% of the main business income respectively. The income and proportion of the products of the company’s own brand are increasing year by year.
During the reporting period, the composition of the company’s revenue from various products and services by agent brand and independent brand is as follows:
(1) Life science research products
During the reporting period, the income and proportion of the company’s life science research products by independent brand and agent brand are as follows:
Unit: 10000 yuan,%
Products January September 20212020 20192018
brand
Proportion of income to income
autonomy
203382 4.65215552 5.03162602 4.78147309 5.93 brand
Scientific research agent
Reagent 4170424 95.354069241 94.973238977 95.222335786 94.07 brand
Total 4373806 100.004284793 100.003401579 100. Jiangsu Rainbow Heavy Industries Co.Ltd(002483) 095 100.00
Scientific research agent
390658 100.00428041 100.00310432 100. Shandongsino-Agriunitedbiotechnologyco.Ltd(003042) 28 100.00 instrument brand
During the reporting period, the company’s life science research products mainly include scientific research reagents and scientific research instruments. Among them, scientific research reagents are mainly agent brands, and the proportion of agent brand income in scientific research reagent income is 94.07%, 95.22%, 94.97% and 95.35% respectively. The sales income of self-produced scientific research reagents continues to increase, accounting for about 5%, and the overall proportion is relatively stable; All scientific research instruments are agent brands, and the amount of revenue continued to grow during the reporting period. (2) Pathological diagnosis products
During the reporting period, the revenue and proportion of the company’s pathological diagnosis products by independent brand and agent brand are as follows:
Unit: 10000 yuan,%
January September 20212020 20192018
Product category and brand
Proportion of income proportion of income
